Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study

Journal of Acquired Immune Deficiency Syndromes

Volumn 74, Issue 2, 2017, Pages 180-184

  Post, Frank A ^a   Tebas, Pablo ^b   Clarke, Amanda ^c   Cotte, Laurent ^d   Short, William R ^b   Abram, Michael E ^e   Jiang, Shuping ^e   Cheng, Andrew ^e   Das, Moupali ^e   Fordyce, Marshall W ^e  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UK   (United Kingdom)

^d CROIX ROUSSE HOSPITAL   (France)

^e GILEAD SCIENCES   (United States)

Author keywords

Bone mineral density; Chronic kidney disease; Emtricitabine; HIV; Tenofovir alafenamide

Indexed keywords

ABACAVIR; ALBUMIN; BETA 2 MICROGLOBULIN; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR ALAFENAMIDE; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE; RETINOL BINDING PROTEIN; TENOFOVIR DISOPROXIL; URIC ACID; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ALBUMINURIA; ANTIVIRAL RESISTANCE; ARTHRALGIA; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CREATININE CLEARANCE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESTIMATED GLOMERULAR FILTRATION RATE; EXCRETION FRACTION; FANCONI RENOTUBULAR SYNDROME; FRACTURE; GENOTYPE; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MIDDLE AGED; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PRIORITY JOURNAL; PROTEINURIA; SPINE; UPPER RESPIRATORY TRACT INFECTION; VIREMIA; ADOLESCENT; AGED; BLOOD; CLINICAL TRIAL; COMPLICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; KIDNEY FAILURE; KIDNEY FUNCTION TEST; MALE; METABOLIC CLEARANCE RATE; PROCEDURES; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; VERY ELDERLY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CREATININE; HIV INFECTIONS; HUMANS; KIDNEY FUNCTION TESTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROTEINURIA; RENAL INSUFFICIENCY; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84988711014     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000001186     Document Type: Conference Paper

References (26)

1. Schwartz EJ, Szczech LA, Ross MJ, et al. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol. 2005;16:2412-2420.
2. Wyatt CM, Winston JA, Malvestutto CD, et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS. 2007;21:2101-2103.
3. Linley L, Prejean J, Qian A, et al. Racial/ethnic disparities in HIV diagnoses among persons aged 50 years and older in 37 US States, 2005-2008. Am J Public Health. 2012;102:1527-1534.
4. Adekeye OA, Heiman HJ, Onyeabor OS, et al. The new invincibles: HIV screening among older adults in the US. PLoS One. 2012;7:e43618.
5. Hall AM, Hendry BM, Nitsch D, et al. Tenofovir-associated kidney toxicity in HIV-infected patients: A review of the evidence. Am J Kidney Dis. 2011;57:773-780.
6. D:A:D Study Group, Sabin CA, Worm SW, Reiss P, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration. Lancet. 2008;371:1417-1426.
7. Günthard HF, Saag MS, Benson CA, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016;316:191-210.
8. Van Rompay KK, Durand-Gasselin L, Brignolo LL, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother. 2008;52:3144-3160.
9. Fux CA, Simcock M, Wolbers M, et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the swiss HIV cohort study. Antivir Ther. 2007;12:1165-1173.
10. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reversetranscriptase inhibitor-based therapy. J Infect Dis. 2008;197:102-108.
11. Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008;83:265-272.
12. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, doubleblind, phase 3, non-inferiority trials. Lancet. 2015;385:2606-2615.
13. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50:3297-3304.
14. Bam RA, Yant SR, Cihlar T. Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OATdependent cytotoxicity. Antivir Ther. 2014;19:687-692.
15. Wohl D, Oka S, Clumeck N, et al. Brief report: A randomized, doubleblind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. J Acquir Immune Defic Syndr. 2016;72:58-64.
16. Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: A randomised, active-controlled, multicentre, open-label, phase 3, noninferiority study. Lancet Infect Dis. 2016;16:43-52.
17. Rivero A, Pulido F, Caylá J, et al; Grupo de Estudio de Sida (GESIDA), Secretaría del Plan Nacional sobre el Sida. The Spanish AIDS study group and Spanish national AIDS plan (GESIDA/Secretaría del Plan Nacional sobre el Sida) recommendations for the treatment of tuberculosis in HIV-infected individuals (updated january 2013) [in Spanish]. Enferm Infecc Microbiol Clin. 2013;31:672-684.
18. Antinori A, Marcotullio S, Andreoni M, et al; Italian HIV Guidelines Working Group. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015. New Microbiol. 2016;39:93-109.
19. Snopková S, Rozsypal H, Aster V, et al. Guidelines for caring for HIVinfected adults and post-exposure prophylaxis of HIV infection [Article in Czech]. Klin Mikrobiol Infekc Lek. 2016;22:20-38.
20. German-Austrian HIV Treatment Guidelines. 2016. Available at: http://www.daignet.de/site-content/hiv-therapie/leitlinien-1/Anlage%201%20LL% 20055-001%20Version%206%2011-12-2015%20endgultige%20Version% 20rev-2.pdf. Accessed September 10, 2016.
21. Pozniak A, Arribas JR, Gathe J, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48 week results from a single-arm, multi-center, open-label, phase 3 study. J Acquir Immune Defic Syndr. 2016;71:530-537.
22. Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010;24:1781-1784.
23. Santos JR, Saumoy M, Curran A, et al. The lipid-lowering effect of tenofovir/emtricitabine: A randomized, crossover, double-blind, placebocontrolled trial. Clin Infect Dis. 2015;61:403-408.
24. Behrens G, Maserati R, Rieger A, et al. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. Antivir Ther. 2012;17:1011-1020.
25. Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: A position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis. 2003;42:617-622.
26. Kudo K, Konta T, Mashima Y, et al. The association between renal tubular damage and rapid renal deterioration in the Japanese population: The takahata study. Clin Exp Nephrol. 2011;15:235-241.